secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2023-10-17T23:59:59+00:00
Accession:  0000950170-23-053645
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta gets FDA IND clearance for NKX019 in LN; cuts workforce 10%, extends cash runway
--------------------------------------------------------------------------------

- FDA cleared IND for NKX019 (CAR NK) for lupus nephritis; enrollment starts H1 2024; up to 12 patients.
- RIF of 18 employees (~10% workforce); $1M-$1.5M severance costs in Q4 2023; extends cash runway into 2026.
- Preliminary cash $278.4M as of Sep 30, 2023; cash runway extended one year into 2026.
- NKX019 NHL: new compressed dosing cohort (Days 0,3,7) for LBCL; prior expansion cohorts discontinued.
- Clinical updates in 2024: NKX101 AML H1, NKX019 NHL mid-2024, NKX019 LN in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/0000950170-23-053645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/nktx-20231016.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer